Phase II study of Paclitaxel and Nedaplatin for previously untreated patients with advanced squamous cell lung cancer.

Phase II study of Paclitaxel and Nedaplatin for previously untreated patients with advanced squamous cell lung cancer. - Phase II study of Paclitaxel and Nedaplatin for previously untreated patients with advanced squamous cell lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008872

Enrollment

Registered

2012-09-06

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell lung cancer

Interventions

Paclitaxel+Nedaplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically confirmed Stage IIIB/IV squamous cell lung cancer. 2.Previously untreated patients with chemotherapy. 3.With one or more measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) ver.1.1. 4.Age20<= 5.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. 6.Adequate function of vital organs, including normal hematopoietic function, normal liver function and normal renal function. 7.A life expectancy of more than 3 months. 8.All patients provided written informed consent before initiation of study-related procedures.

Exclusion criteria

Exclusion criteria: 1.Symptomatic Brain metastasis. 2.History of active double cancer. 3.Severe infection. 4.Severe comorbidity (heart failure Tendency to hemorrhages uncontrollable hypertension, uncontrollable diabetes, etc) 5.Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 6.With a history of drug sensitivity. 7.Pregnant or lactating women or those who declined contraception. 8.Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactTakashi Kasai

Tochigi Cancer Center Division of Thoracic Oncology

takasai@tcc.pref.tochigi.lg.jp028-658-5151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026